Company Overview

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer. The company operates within the biotechnology and cell therapy industries, with a primary emphasis on hematologic malignancies and solid tumors. Unlike autologous CAR T therapies that use a patient’s own cells, Allogene’s platform is designed to manufacture “off-the-shelf” CAR T products from healthy donor T cells, with the goal of improving scalability, reducing manufacturing time, and broadening patient access. The company’s principal revenue activity has historically consisted of collaboration agreements and licensing arrangements, as it remains in the clinical development stage and has not commercialized products as of publicly available filings through 2024.

Key programs include candidates targeting CD19 and other tumor-associated antigens, supported by proprietary gene-editing and cell engineering technologies. Allogene was founded in 2017 by former Kite Pharma executives and biotechnology investors, including collaborations with academic and industry partners. The company’s strategic positioning is centered on industrial-scale manufacturing of allogeneic cell therapies and leveraging gene-editing approaches intended to reduce graft-versus-host disease and immune rejection risks.

Business Operations

Allogene’s operations are primarily organized around research, clinical development, manufacturing, and commercialization planning for allogeneic CAR T therapies. Its core business activities include advancing investigational products through clinical trials, developing proprietary manufacturing capabilities, and expanding intellectual property associated with engineered T-cell therapies. Major pipeline assets have included ALLO-501, ALLO-501A, ALLO-715, and solid tumor programs developed through internal research and external partnerships. The company generates funding primarily through equity financing, strategic collaborations, and licensing agreements rather than commercial product sales.

The company operates principally in the United States but maintains relationships and clinical activities internationally through research institutions, manufacturing partners, and clinical trial sites. Allogene’s technology platform incorporates gene-editing tools licensed from third parties, including TALEN technology associated with Cellectis S.A. The company also established manufacturing and development capabilities intended to support scalable production of allogeneic cell therapies. Strategic collaborations have included partnerships with Servier, Pfizer, and academic cancer centers involved in cellular immunotherapy research.

Strategic Position & Investments

Allogene’s strategic direction has focused on advancing next-generation allogeneic CAR T therapies that can compete with or complement existing autologous approaches. The company has invested heavily in clinical development programs targeting non-Hodgkin lymphoma, multiple myeloma, and solid tumors, while also pursuing innovations designed to improve persistence, safety, and resistance to host immune rejection. Its strategy emphasizes reducing manufacturing complexity and treatment delays associated with patient-specific therapies.

Notable strategic activities have included the acquisition of assets and rights from Pfizer related to allogeneic CAR T development and continued investment in manufacturing infrastructure and gene-editing technologies. The company has also explored emerging areas such as dual-targeting CAR constructs and advanced lymphodepletion approaches. Subsidiary and partnership structures have largely been oriented toward intellectual property access, clinical collaboration, and scalable production capabilities rather than broad diversification into unrelated business segments.

Geographic Footprint

Allogene Therapeutics is headquartered in South San Francisco, California, and its operations are concentrated primarily in the United States. The company conducts clinical trials across multiple research centers and maintains relationships with biotechnology and pharmaceutical partners in North America and Europe. Its operational footprint reflects the global nature of oncology clinical development, including regulatory engagement and multicenter trial activity.

The company’s international exposure is also influenced by licensing and technology agreements with foreign biotechnology organizations, particularly in the gene-editing field. Through collaborations and supplier relationships, Allogene maintains operational and strategic ties across major biotechnology markets, though its physical infrastructure and employee base remain primarily U.S.-centered according to public regulatory filings and investor disclosures.

Leadership & Governance

Allogene Therapeutics was co-founded by biotechnology executives and investors associated with the development of early CAR T therapies, including leaders formerly connected to Kite Pharma. The company’s governance and strategic vision have emphasized accelerating access to cell therapy through scalable allogeneic platforms, disciplined clinical development, and manufacturing standardization.

Key members of leadership have included:

• David Chang – Co-Founder and former President, Chief Executive Officer
• David Galbraith – President and Chief Executive Officer
• Rafael Amado – President of Research and Development and former Chief Medical Officer
• Eric Schmidt – Chief Financial Officer
• Zachary Roberts – Executive Vice President, Research and Development and Chief Medical Officer
• Arie Belldegrun – Executive Chairman and Co-Founder

The company’s leadership philosophy has consistently centered on translating cell therapy innovation into commercially scalable oncology treatments while maintaining a focus on clinical execution, regulatory engagement, and manufacturing efficiency. Public disclosures, including SEC filings, investor presentations, and earnings materials, have emphasized long-term platform development over near-term commercialization.